Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this ...
SARASOTA, FL, UNITED STATES, January 28, 2026 /EINPresswire.com/ — Identifyn ®, a leader in super-resolution applications and discovery tools, is proud to announce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results